The Correlation Study between Plasma Aβ Proteins and Cerebrospinal Fluid Alzheimer’s Disease Biomarkers
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β proteins (Aβ). In this study we explored the correlation of plasma Aβ40 and Aβ42 concentrations with Aβ42, total tau (tTau) and phosphorylated tau 181 (pTau181) levels in cerebrospinal fluid (CSF) in AD and control subjects to further understand the characteristics of plasma Aβ proteins levels. Methods The consecutive subjects (44 AD and 47 controls) in this study were recruited. The plasma levels of Aβ40 and Aβ42 were measured using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kits. And the corresponding CSFs were analyzed in terms of Aβ42, tTau and pTau181 concentrations using INNOTEST ELISA kits. Further, the albumin levels were measured both in serum and CSF and albumin ratio was obtained to check the integrity of blood-brain barrier. Results CSF Aβ42 concentrations were significantly decreased while tTau and pTau181 levels were significantly increased in AD subjects. The plasma levels of Aβ42 were significantly lower (p=0.007), while the Aβ40/Aβ42 ratio was significantly higher (p<0.001) in AD patients than in controls. The overall plasma Aβ42 levels showed a positive correlation with those of CSF Aβ42 (p=0.001), but not with the others in CSF. In subgroup analysis, the CSF Aβ42 demonstrated positive correlation with not only plasma Aβ42 but also Aβ40 levels in controls. However, no significant relationship was noted between plasma and CSF Aβ proteins in AD group. Conclusions The plasma Aβ42 and Aβ40 concentrations were shown to have a close relationship with CSF Aβ42 levels in controls, but not in AD subjects. Our results suggest that the correlation between plasma Aβ40 and CSF Aβ42 levels is perturbed in AD.
Abstract
Background and Purpose Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β proteins (Aβ). In this study we explored the correlation of plasma Aβ40 and Aβ42 concentrations with Aβ42, total tau (tTau) and phosphorylated tau 181 (pTau181) levels in cerebrospinal fluid (CSF) in AD and control subjects to further understand the characteristics of plasma Aβ proteins levels. Methods The consecutive subjects (44 AD and 47 controls) in this study were recruited. The plasma levels of Aβ40 and Aβ42 were measured using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kits. And the corresponding CSFs were analyzed in terms of Aβ42, tTau and pTau181 concentrations using INNOTEST ELISA kits. Further, the albumin levels were measured both in serum and CSF and albumin ratio was obtained to check the integrity of blood-brain barrier. Results CSF Aβ42 concentrations were significantly decreased while tTau and pTau181 levels were significantly increased in AD subjects. The plasma levels of Aβ42 were significantly lower (p=0.007), while the Aβ40/Aβ42 ratio was significantly higher (p<0.001) in AD patients than in controls. The overall plasma Aβ42 levels showed a positive correlation with those of CSF Aβ42 (p=0.001), but not with the others in CSF. In subgroup analysis, the CSF Aβ42 demonstrated positive correlation with not only plasma Aβ42 but also Aβ40 levels in controls. However, no significant relationship was noted between plasma and CSF Aβ proteins in AD group. Conclusions The plasma Aβ42 and Aβ40 concentrations were shown to have a close relationship with CSF Aβ42 levels in controls, but not in AD subjects. Our results suggest that the correlation between plasma Aβ40 and CSF Aβ42 levels is perturbed in AD.
참고문헌 (32)
- Kelly Jennings ND, "Amyloid B protein of Alzheimers disease: more than just a plaque", Nat Med J (2010)
- Förstl H, "Clinical features of Alzheimer’s disease", Eur Arch Psychiatry Clin Neurosci, 249, pp.288~290 (1999)
- Jack CR Jr, "Biomarker modeling of Alzheimer’s disease", Neuron, 80, pp.1347~1358 (2013)
- Dubois B, "Advancing research diagnostic criteria for Alzheimer’s disease : the IWG-2 criteria", Lancet Neurol, 13, pp.614~629 (2014)
- Koyama A, "Plasma amyloid-β as a predictor of dementia and cognitive decline : a systematic review and meta-analysis", Arch Neurol, 69, pp.824~831 (2012)
- Rissman RA, "Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease", J Neural Transm(Vienna), 119, pp.843~850 (2012)
- Toledo JB, "Plasma amyloid beta measurements-a desired but elusive Alzheimer’s disease biomarker", Alzheimers Res Ther, 5, pp.8~ (2013)
- Rembach A, "Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer’s disease as measured by cognitive decline and change in neocortical amyloid burden", J Alzheimers Dis, 40, pp.95~104 (2014)
- Chen M, "Platelets are the primary source of amyloid beta-peptide in human blood", Biochem Biophys Res Commun, 213, pp.96~103 (1995)
- 42 and Alzheimer’s disease : relation to age, mortality, and risk, "Neurology", 2003, 1185~1190
- Toledo JB, "Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI", Acta Neuropathol, 122, pp.401~413 (2011)
- Metti AL, "The demographic and medical correlates of plasma aβ40 and aβ42", Alzheimer Dis Assoc Disord, 27, pp.244~249 (2013)
- Wilson MR, "Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity", Mol Biosyst, 4, pp.42~52 (2008)
- Kim HJ, "Elevation of the plasma Aβ40", Aβ42 ratio as a diagnostic marker of sporadic earlyonset Alzheimer’s disease, 2015, pp.48, 1043~1050
- McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
- Kang Y, "A validity study on the Korean Mini-Mental State Examination(K-MMSE)in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
- 안현정, "Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients", Journal of Korean Medical Science, 25(7), pp.1071~1076 (2010), 대한의학회
- 박선아, "A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease", Journal of Clinical Neurology, 11(2), pp.132~141 (2015), 대한신경과학회[DOI]
- Feng C, "Log-transformation and its implications for data analysis", Shanghai Arch Psychiatry, 26, pp.105~109 (2014)
- Wada H, "Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio", Intern Med, 37, pp.509~513 (1998)
- Wang L, "Cerebrospinal fluid Aβ42, phosphorylated Tau181, and restingstate functional connectivity", JAMA Neurol, 70, pp.1242~1248 (2013)
- Wahlund LO, "Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients", Neurosci Lett, 339, pp.99~102 (2003)
- Fagan AM, "Decreased cerebrospinal fluid Abeta(42)correlates with brain atrophy in cognitively normal elderly", Ann Neurol, 65, pp.176~183 (2009)
- Chouraki V, "Plasma amyloid-β and risk of Alzheimer’s disease in the framingham heart study", Alzheimers Dement, 11, pp.249~257 (2015)
- Lui JK, "Plasma amyloid-beta as a biomarker in Alzheimer’s disease : the AIBL study of aging", J Alzheimers Dis, 20, pp.1233~1242 (2010)
- Pesaresi M, "Plasma levels of beta-amyloid(1-42)in Alzheimer’s disease and mild cognitive impairment", Neurobiol Aging, 27, pp.904~905 (2006)
- Song F, "Meta-analysis of plasma amyloid-β levels in Alzheimer’s disease", J Alzheimers Dis, 26, pp.365~375 (2011)
- Takeda S, "Plasma beta-amyloid as potential biomarker of Alzheimer disease : possibility of diagnostic tool for Alzheimer disease", Mol Biosyst, 6, pp.1760~1766 (2010)
- Querfurth HW, "Alzheimer’s disease", N Engl J Med, 362, pp.329~344 (2010)
- Huang Y, "β-amyloid dynamics in human plasma", Arch Neurol, 69, pp.1591~1597 (2012)
- Hansson O, "Evaluation of plasma Abeta(40)and Abeta(42)as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment", Neurobiol Aging, 31, pp.357~367 (2010)
- Le Bastard N, "No correlation between time-linked plasma and CSF Abeta levels", Neurochem Int, 55, pp.820~825 (2009)